S&P 500   4,533.16 (-0.96%)
DOW   34,514.96 (-0.36%)
QQQ   382.30 (-1.95%)
AAPL   162.27 (-0.91%)
MSFT   322.35 (-2.17%)
FB   305.37 (-1.62%)
GOOGL   2,820.90 (-1.34%)
AMZN   3,386.93 (-1.47%)
TSLA   1,016.26 (-6.30%)
NVDA   305.30 (-4.97%)
BABA   112.52 (-7.77%)
NIO   33.21 (-8.26%)
CGC   10.13 (-2.22%)
AMD   141.70 (-5.96%)
GE   93.00 (-2.34%)
MU   82.29 (-0.71%)
T   23.35 (+1.30%)
F   19.39 (-2.42%)
DIS   146.08 (-0.76%)
PFE   53.64 (+1.13%)
AMC   27.94 (-7.73%)
ACB   5.94 (-3.26%)
BA   197.30 (-2.51%)
S&P 500   4,533.16 (-0.96%)
DOW   34,514.96 (-0.36%)
QQQ   382.30 (-1.95%)
AAPL   162.27 (-0.91%)
MSFT   322.35 (-2.17%)
FB   305.37 (-1.62%)
GOOGL   2,820.90 (-1.34%)
AMZN   3,386.93 (-1.47%)
TSLA   1,016.26 (-6.30%)
NVDA   305.30 (-4.97%)
BABA   112.52 (-7.77%)
NIO   33.21 (-8.26%)
CGC   10.13 (-2.22%)
AMD   141.70 (-5.96%)
GE   93.00 (-2.34%)
MU   82.29 (-0.71%)
T   23.35 (+1.30%)
F   19.39 (-2.42%)
DIS   146.08 (-0.76%)
PFE   53.64 (+1.13%)
AMC   27.94 (-7.73%)
ACB   5.94 (-3.26%)
BA   197.30 (-2.51%)
S&P 500   4,533.16 (-0.96%)
DOW   34,514.96 (-0.36%)
QQQ   382.30 (-1.95%)
AAPL   162.27 (-0.91%)
MSFT   322.35 (-2.17%)
FB   305.37 (-1.62%)
GOOGL   2,820.90 (-1.34%)
AMZN   3,386.93 (-1.47%)
TSLA   1,016.26 (-6.30%)
NVDA   305.30 (-4.97%)
BABA   112.52 (-7.77%)
NIO   33.21 (-8.26%)
CGC   10.13 (-2.22%)
AMD   141.70 (-5.96%)
GE   93.00 (-2.34%)
MU   82.29 (-0.71%)
T   23.35 (+1.30%)
F   19.39 (-2.42%)
DIS   146.08 (-0.76%)
PFE   53.64 (+1.13%)
AMC   27.94 (-7.73%)
ACB   5.94 (-3.26%)
BA   197.30 (-2.51%)
S&P 500   4,533.16 (-0.96%)
DOW   34,514.96 (-0.36%)
QQQ   382.30 (-1.95%)
AAPL   162.27 (-0.91%)
MSFT   322.35 (-2.17%)
FB   305.37 (-1.62%)
GOOGL   2,820.90 (-1.34%)
AMZN   3,386.93 (-1.47%)
TSLA   1,016.26 (-6.30%)
NVDA   305.30 (-4.97%)
BABA   112.52 (-7.77%)
NIO   33.21 (-8.26%)
CGC   10.13 (-2.22%)
AMD   141.70 (-5.96%)
GE   93.00 (-2.34%)
MU   82.29 (-0.71%)
T   23.35 (+1.30%)
F   19.39 (-2.42%)
DIS   146.08 (-0.76%)
PFE   53.64 (+1.13%)
AMC   27.94 (-7.73%)
ACB   5.94 (-3.26%)
BA   197.30 (-2.51%)
NASDAQ:TCRR

TCR2 Therapeutics Earnings Date, Estimates, & History

$5.11
-0.12 (-2.29%)
(As of 12/3/2021 11:22 AM ET)
Add
Compare
Today's Range
$5.02
$5.27
50-Day Range
$5.02
$9.03
52-Week Range
$4.96
$35.86
Volume
13,267 shs
Average Volume
552,196 shs
Market Capitalization
$195.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.15

Earnings Summary

Upcoming
Earnings Date
Mar. 10
Estimated

Actual EPS
(Nov. 10)
-$0.69
Missed By -$0.06

Consensus EPS
(Nov. 10)
-$0.63

Last Year's Q4 EPS
(11/12/2020)
-$0.56

Skip Charts & View Estimated and Actual Earnings Data

TCR2 Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TCR2 Therapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

TCR2 Therapeutics (NASDAQ:TCRR) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20214($0.65)($0.53)($0.59)
Q2 20215($0.75)($0.57)($0.63)
Q3 20215($0.85)($0.52)($0.66)
Q4 20215($1.00)($0.69)($0.78)
FY 202119($3.25)($2.31)($2.65)
Q1 20223($0.71)($0.66)($0.69)
Q2 20223($0.75)($0.58)($0.67)
Q3 20223($0.80)($0.58)($0.70)
Q4 20223($1.05)($0.60)($0.81)
FY 202212($3.31)($2.42)($2.87)

TCRR Earnings Information

TCR2 Therapeutics last issued its quarterly earnings results on November 10th, 2021. The reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.06. TCR2 Therapeutics has generated ($2.46) earnings per share over the last year (($2.46) diluted earnings per share). Earnings for TCR2 Therapeutics are expected to decrease in the coming year, from ($2.61) to ($2.86) per share. TCR2 Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 10th, 2022 based off prior year's report dates.

TCR2 Therapeutics (NASDAQ:TCRR) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
3/10/2022
(Estimated)
        
11/10/20219/30/2021($0.63)($0.69)($0.06)($0.69)
8/5/20216/30/2021($0.60)($0.64)($0.04)($0.64)
5/13/2021Q1 2021($0.55)($0.58)($0.03)($0.58)
3/11/202112/31/2020($0.55)($0.55)($0.55)
11/12/20209/30/2020($0.52)($0.56)($0.04)($0.56)
8/12/20206/30/2020($0.65)($0.67)($0.02)($0.67)
5/14/20203/31/2020($0.60)($0.65)($0.05)($0.65)
3/30/202012/31/2019($0.64)($0.54)+$0.10($0.54)
11/12/2019Q3($0.5520)($0.58)($0.0280)($0.58)
8/8/2019Q2 2019($0.57)($0.4645)+$0.1055($0.46)
5/13/20193/31/2019($0.38)($4.85)($4.47)($4.85)  
4/1/2019Q4 2018($0.38)($16.22)($15.84)($16.22)
(Earnings results data provided by Zacks Investment Research)












TCR2 Therapeutics (NASDAQ:TCRR) Earnings Frequently Asked Questions

When is TCR2 Therapeutics's earnings date?

TCR2 Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 10th, 2022 based off last year's report dates. Learn more on TCRR's earnings history

Did TCR2 Therapeutics beat their earnings estimates last quarter?

In the previous quarter, TCR2 Therapeutics (NASDAQ:TCRR) missed the analysts' consensus estimate of ($0.63) by $0.06 with a reported earnings per share (EPS) of ($0.69). Learn more on TCRR's earnings details

How much profit does TCR2 Therapeutics generate each year?

TCR2 Therapeutics (NASDAQ:TCRR) has a recorded net income of -$67.12 million. TCRR has generated -$2.46 earnings per share over the last four quarters.

What is TCR2 Therapeutics's EPS forecast for next year?

TCR2 Therapeutics's earnings are expected to decrease from ($2.61) per share to ($2.86) per share in the next year.

This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.